Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
公司公告
COPENHAGEN, Denmark; February 28, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,359 shares as a consequence of the exercise of employee warrants.
丹麦哥本哈根；2023 年 2 月 28 日 — Genmab A/S 由于行使员工认股权证，纳斯达克股票代码：GMAB）将把股本增加24,359股。
The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
此次增持是在公司或其他公司的现有股东没有任何优先购买权的情况下进行的。这些股票以现金形式认购，每股名义价格为1丹麦克朗：
2,725 shares at DKK 815.50,
163 shares at DKK 962.00,
804 shares at DKK 1,025.00,
93 shares at DKK 1,032.00,
1,107 shares at DKK 1,050.00,
80 shares at DKK 1,136.00,
525 shares at DKK 1,145.00,
444 shares at DKK 1,147.50,
428 shares at DKK 1,155.00,
591 shares at DKK 1,161.00,
580 shares at DKK 1,210.00,
799 shares at DKK 1,233.00,
3,526 shares at DKK 1,334.50,
8,400 shares at DKK 1,427.00, and
4,094 shares at DKK 1,615.00.
2,725 股，报价 815.50 丹麦克朗，
163 股，报价 962.00 丹麦克朗，
804 股，价格为 1,025.00 丹麦克朗，
93 股，报价 1,032.00 丹麦克朗，
1,107 股，价格为 1,050.00 丹麦克朗，
80 股，报价 1,136.00 丹麦克朗，
525 股，价格为 1,145.00 丹麦克朗，
444 股，价格为 1,147.50 丹麦克朗，
428 股，价格为 1,155.00 丹麦克朗，
591 股，报价 1,161.00 丹麦克朗，
580 股，价格为 1,210.00 丹麦克朗，
799 股，价格为 1,233.00 丹麦克朗，
3,526股股票，价格为1,334.50丹麦克朗，
8,400 股股票，价格为 1,427.00 丹麦克朗，以及
4,094股，价格为1,615.00丹麦克朗。
Proceeds to the company are approximately DKK 31.8 million. The increase corresponds to approximately 0.04% of the company's share capital.
该公司的收益约为3180万丹麦克朗。增幅约相当于公司股本的0.04％。
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.
新股是普通股，没有任何特殊权利，是可自由转让的流通票据。新股授予股息权以及认购时与公司有关的其他权利。新股将在丹麦商业管理局注册后在纳斯达克哥本哈根上市。增资预计将很快完成。
Pursuant to section 32 of the Danish Capital Markets Act No. 41 of January 13, 2023, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 65,985,932 which is made up of 65,985,932 shares of a nominal value of DKK 1 each, corresponding to 65,985,932 votes.
根据2023年1月13日第41号《丹麦资本市场法》第32条，特此宣布，增资后的Genmab A/S股本的总名义价值为65,985,932丹麦克朗，由65,985,932股股票组成，每股面值为1丹麦克朗，相当于65,985,932张选票。
About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.
关于 Genmab
Genmab 是一家国际生物技术公司，其核心目标是指导其不可阻挡的团队努力通过创新和差异化的抗体疗法改善患者的生活。20 多年来，其充满激情、富有创新精神和协作精神的团队发明了下一代抗体技术平台，并利用转化研究和数据科学，从而形成了包括双特异性 T 细胞参与剂、下一代免疫检查点调节剂、效应功能增强抗体和抗体药物偶联物的专有产品线。为了帮助开发和向患者提供新的抗体疗法，Genmab 已与生物技术和制药公司建立了 20 多个战略合作伙伴关系。到2030年，Genmab的愿景是使用Knock-Your-Socks-Off（KYSO）抗体药物改变癌症和其他严重疾病患者的生活。
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Genmab 成立于 1999 年，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿和日本东京设有办事处。欲了解更多信息，请访问 Genmab.com 并在 twitter.com/genmab 上关注我们。
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
联系人：
Marisol Peron，全球传播与企业事务高级副总裁
T: +1 609 524 0065；E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.
安德鲁·卡尔森，副总裁，投资者关系主管
T: +45 3377 9558；E: acn@genmab.com
本公司公告包含前瞻性陈述。“相信”、“期望”、“预期”、“打算” 和 “计划” 等词语以及类似的表达方式表示前瞻性陈述。实际业绩或表现可能与此类陈述所表达或暗示的任何未来业绩或表现存在重大差异。可能导致我们的实际结果或表现存在重大差异的重要因素包括与产品临床前和临床开发相关的风险、与临床试验结果和进行相关的不确定性，包括不可预见的安全问题、与产品制造相关的不确定性、我们的产品缺乏市场接受度、我们无法管理增长、与业务领域和市场相关的竞争环境、我们无法吸引和留住具有适当资格的人员，我们的专利和所有权不可执行或缺乏保护、我们与关联实体的关系、可能使我们的产品或技术过时的技术变化和发展以及其他因素。有关这些风险的进一步讨论，请参阅 Genmab 最新财务报告中的风险管理部分，这些部分可在 以及 Genmab 最新的 20-F 表年度报告和其他文件中包含的风险因素 与美国证券交易委员会 (SEC) 联系，可在以下网址获得 www.sec.gov。除非法律要求，否则Genmab不承担任何义务更新或修改本公司公告中的前瞻性陈述，也不承担任何义务确认此类陈述以反映发布之日后的后续事件或情况或与实际业绩有关的事件或情况。
Genmab A/S 和/或其子公司拥有以下商标：Genmab®; Y 形的 Genmab 徽标®; Genmab 与 Y 形的 Genmab 徽标相结合®; HuMax®; duoBody®; DuoBody 与 DuoBody 徽标相结合®; HexAbody®; HexAbody 与 HexAbody 徽标结合使用®; duohexAbody® 还有 HexELE®。
Company Announcement no. 12
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
公司公告第 12 号
CVR 号 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Genmab A/S
Kalvebod Brygge 43
1560 哥本哈根 V
丹麦
Attachment
附件
- 280223_CA12_Warrant Exercise_
- 280223_ca12_认股权证行使_
译文内容由第三方软件翻译。